Sequencing & Future Combination Strategies for BPCDN

In this final segment, Dr Luskin discusses treatment sequencing considerations in blastic plasmacytoid dendritic cell neoplasm (BPDCN), with a focus on integrating targeted therapy and allogeneic stem cell transplantation. She outlines how early planning and timely referral for transplant evaluation can be incorporated alongside initial therapy, emphasizing the role of targeted treatment as a bridge to longer-term disease control. The discussion highlights how this sequencing approach may optimize outcomes by positioning patients for durable remission. Dr Luskin also looks ahead to emerging therapeutic strategies, including early data on combination and triplet regimens that aim to improve responses beyond what is achievable with single-agent therapy. She provides perspective on how these evolving approaches may influence future BPDCN management and underscores the importance of collaboration, education, and infrastructure readiness as community oncology practices prepare to safely adopt new treatment options. Without detailing investigational protocols, this segment offers a forward-looking view of how BPDCN care may continue to evolve.